DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Information source: Centocor, Inc.
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer, Prostate

Intervention: Mitoxantrone (Drug); Siltuximab (Drug); Prednisone (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Centocor, Inc.

Official(s) and/or principal investigator(s):
Centocor, Inc. Clinical Trial, Study Director, Affiliation: Centocor, Inc.


The purpose of this study is to assess the safety and efficacy of siltuximab administered in combination with mitoxantrone and prednisone in participants with metastatic (spread of cancer cells from one part of the body to another) hormone-refractory (not responding to treatment) prostate cancer (abnormal tissue that grows and spreads in the body) (HRPC).

Clinical Details

Official title: A Phase 2, Multicenter, Open-Label Study of CNTO 328 (Anti-IL-6 Monoclonal Antibody) in Combination With Mitoxantrone Versus Mitoxantrone in Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome:

Part 1: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

Part 2: Progression Free Survival (PFS)

Secondary outcome:

Time to Clinical Deterioration (TtCD)

Number of Participants With Palliative Response

Number of Participants With Prostate Specific Antigen (PSA) Response

Overall Survival (OS)

Detailed description: This is a 2-part, open-label (all people know the identity of the intervention) multicenter (when more than 1 hospital or medical school team work on a medical research study), Phase 2 study to evaluate the safety and efficacy of the combination of siltuximab plus mitoxantrone versus mitoxantrone in participants with metastatic HRPC who have received 1 prior Docetaxel-based chemotherapy (treatment of disease, usually cancer, by chemical agents) regimen (pattern of giving treatment). Part 1 of the study is single arm where participants will receive mitoxantrone, prednisone and siltuximab. Part 2 of the study is randomized portion (the study drug is assigned by chance), consisting of 2-arms. The experimental arm will consist of treatment with mitoxantrone, prednisone and siltuximab. The control arm will consist of treatment with mitoxantrone and prednisone. Mitoxantrone will be administered at a dose of 12 milligram per square meter (mg/m^2) intravenously (into a vein) as a 30-minute infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1 of each 3-week cycle, until disease progression or unacceptable toxicity (any harmful effect of a drug) or up to 10 cycles (a maximum total dose of approximately 120 mg/m^2). Siltuximab will be administered at a dose of 6 mg/kilogram intravenously as a 2-hour infusion, starting Day 1 of Cycle 1 to continue every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year. All participants will receive prednisone 5 mg twice daily starting with the first administration of Mitoxantrone. The duration of treatment will be a maximum of 12 months for cumulative dose. Radiologic assessments will be performed on Week 12 after the first study agent dosing, then every 9 weeks until the end of treatment and then once every 3 months until documented disease progression. Tumor (a mass in a specific area) response will be assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria. There will be short-term follow-up visits (conducted monthly for 2 months), followed by long-term follow-up visits (conducted once every 3 months). Participants' safety will also be monitored throughout the study.


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Male.


Inclusion Criteria:

- Histologically (the study of tissue under the microscope) or cytologically (the study

of cells) confirmed adenocarcinoma (a malignant epithelial tumor with a glandular organization) of the prostate

- Radiologically (Gamma and Computed Topography [CT] scans) documented metastatic


- At least 6 weeks of treatment with 1 prior docetaxel-based chemotherapy for

metastatic Hormone Refractory Prostate Cancer (HRPC)

- Disease progression, during or within 6 months of stopping of prior docetaxel-based

therapy, based on one of the following: serum Prostate Specific Antigen (PSA) progression, defined as a rise in at least 2 consecutive serum PSA values, each obtained at least 1 week apart or radiologic disease progression: if disease progression is shown by bone scan only, then disease progression is defined by the appearance of 2 or more new bone lesions (abnormal area of tissue, such as a wound, sore, rash, or boil)

- Orchiectomy (surgery to remove one or both testicles) or testosterone less than 50

nanogram per decilliter (ng/dL) by means of pharmacological/chemical castration Exclusion Criteria:

- No evidence of a brain tumor

- No more than 1 line of chemotherapy for metastatic prostate cancer

- No prior mitoxantrone treatment

- Prior malignancy (other than prostate cancer) except adequately treated superficial

bladder cancer, basal cell or squamous cell carcinoma (type of cancer) of the skin, or other cancer for which the subject has been disease-free for atleast 3 years

- No Human Immunodeficiency Virus (HIV) (a life-threatening infection that you can get

from an infected person's blood or from having sex with an infected person) seropositivity or hepatitis (inflammation of the liver) B or C infection

Locations and Contacts

Innsbruck, Austria

St Veit An Der Glan, Austria

Wels N/A, Austria

Wien, Austria

Aalst, Belgium

Antwerpen, Belgium

Brasschaat, Belgium

Brussel, Belgium

Roeselare, Belgium

Sint-Niklaas, Belgium

Wilrijk, Belgium

Caen Cedex 1, France

Le Mans Cedex 2, France

Lyon Cedex 08, France

Villejuif, France

Berlin, Germany

Cologne, Germany

Kassel, Germany

Barcelona N/A, Spain

Barcelona, Spain

Madrid N/A, Spain

Madrid, Spain

Málaga, Spain

London, United Kingdom

Sutton, United Kingdom

Norwalk, Connecticut, United States

Port Saint Lucie, Florida, United States

Atlanta, Georgia, United States

Shreveport, Louisiana, United States

Baltimore, Maryland, United States

Saint Louis, Missouri, United States

New York, New York, United States

Philadelphia, Pennsylvania, United States

Charleston, South Carolina, United States

N Charleston, South Carolina, United States

Milwaukee, Wisconsin, United States

Additional Information

Starting date: November 2006
Last updated: August 18, 2014

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017